Ozempic has ‘very rare’ sight loss side effect, EU drugs regulator finds

The European Medicines Agency (EMA) has identified a "very rare" but increased risk of non-arteritic anterior ischemic optic neuropathy (NAION), a vision-threatening eye condition, in patients taking semaglutide-based drugs like Wegovy and Ozempic. The EMA's review indicated that semaglutide exposure in diabetic patients is linked to a twofold increase in NAION risk compared to those not taking the medication, prompting the regulator to request that NAION be listed as a "very rare" side effect on product information.

Analysis

The European Medicines Agency's (EMA) drug safety committee (PRAC) has identified non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition leading to potential vision loss, as a "very rare" side effect associated with semaglutide, the active ingredient in Novo Nordisk's (NVO) key drugs Ozempic, Wegovy, and Rybelsus. This finding, with an incidence rate of up to one in 10,000 users, follows a review initiated in January. Significantly, the EMA noted a twofold increased risk of NAION in diabetic patients exposed to semaglutide compared to non-users. The PRAC has consequently requested an update to the product information for these medications to include NAION, a decision awaiting final sign-off from the European Commission. This regulatory development introduces a new, albeit low-probability, safety concern for Novo Nordisk's critical GLP-1 franchise, potentially impacting physician and patient risk assessment and inviting further scrutiny. The moderately negative sentiment (-0.6) and moderate market impact score (0.6) reflect the potential for this news to weigh on investor perception regarding the long-term safety profile of these widely prescribed treatments.

Key Decisions for Investors

• Investors should closely monitor the European Commission's final decision on the product information update and any subsequent reviews or actions by other major regulatory bodies, such as the FDA, as this could have broader implications for Novo Nordisk's semaglutide products.
• Consider the potential, though likely marginal, impact on prescription trends for Ozempic, Wegovy, and Rybelsus if concerns about NAION, despite its rarity, influence patient or prescriber sentiment.
• Factor in the heightened regulatory oversight and potential for increased pharmacovigilance requirements for GLP-1 agonists, as this finding adds to the evolving safety understanding of this drug class.